FDA decision: Brepocitinib by Priovant Therapeutics (in 2026)

Health & MedicineOne-Off5mnd

KalshiBeschikbaarheid controlerenKYC vereist2% kostenGeverifieerde afwikkelingsgegevensGrof gekalibreerd

Huidige impliciete kans

Ja 98%

Marktkwaliteit

44 / 100

Lage kwaliteit

24u volume

€ 0

Liquiditeit

€ 922,9

Lage liquiditeit

Bied / Laat

80.0% / 86.0%

Spread

6.0 pt

Brede spread

Marktdata

Bijgewerkt 22 minuten geleden

17 jun 26, 21:001 jan 27, 4:59

Trends

Uitkomst24uKans

Alleen virtueel geld, geen echt geldGeen financieel advies

Gekozen uitkomst

Yes98%

Inzet (USDT)

Regels

If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
Brepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases.
Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body.
In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.

Volumetrend

$812

3 jul10d aan data26 jul

Gerelateerde Markten

Hantavirus pandemic in 2026?

€ 91K

Ja: 3%

POLYMARKET

# of views of MrBeast video day 3?

€ 12,9K

26-27M: 93%

POLYMARKET

Ebola pandemic in 2026?

€ 4,9K

Ja: 3%

POLYMARKET

Measles cases in 2026?

Pandemic in 2026?

Cyclosporiasis cases reported in the US in 2026?

€ 1,2K

Above 20k: 34%

KALSHI

Actief in deze onderwerpen

BitcoinBTC$63,338.67-2.91%

EthereumETH$1,875.51-4.52%

SolanaSOL$73.19-4.29%

DogecoinDOGE$0.0701-3.67%

XRPXRP$1.05-4.88%

BNBBNB$565.62-1.13%

Gerelateerd Nieuws

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Regels

If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
Brepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases.
Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body.
In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.

FDA decision: Brepocitinib by Priovant Therapeutics (in 2026)

Health & MedicineOne-Off5mnd

KalshiBeschikbaarheid controlerenKYC vereist2% kostenGeverifieerde afwikkelingsgegevensGrof gekalibreerd

Huidige impliciete kans

Ja 98%

Marktkwaliteit

44 / 100

Lage kwaliteit

24u volume

€ 0

Liquiditeit

€ 922,9

Lage liquiditeit

Bied / Laat

80.0% / 86.0%

Spread

6.0 pt

Brede spread

Marktdata

Bijgewerkt 22 minuten geleden

17 jun 26, 21:001 jan 27, 4:59

Trends

Uitkomst24uKans

Alleen virtueel geld, geen echt geldGeen financieel advies

Gekozen uitkomst

Yes98%

Inzet (USDT)

Regels

If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
Brepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases.
Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body.
In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.

Volumetrend

$812

3 jul10d aan data26 jul

Gerelateerde Markten

Hantavirus pandemic in 2026?

€ 91K

Ja: 3%

POLYMARKET

# of views of MrBeast video day 3?

€ 12,9K

26-27M: 93%

POLYMARKET

Ebola pandemic in 2026?

€ 4,9K

Ja: 3%

POLYMARKET

Measles cases in 2026?

Pandemic in 2026?

Cyclosporiasis cases reported in the US in 2026?

€ 1,2K

Above 20k: 34%

KALSHI

Actief in deze onderwerpen

BitcoinBTC$63,338.67-2.91%

EthereumETH$1,875.51-4.52%

SolanaSOL$73.19-4.29%

DogecoinDOGE$0.0701-3.67%

XRPXRP$1.05-4.88%

BNBBNB$565.62-1.13%

Gerelateerd Nieuws

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Regels

If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
Brepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases.
Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body.
In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.